Silo Pharma Inc
SILO0.385USD
+0.010+2.69%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
4.03MMarket Cap
LossP/E TTM
More Details of Silo Pharma Inc Company
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
Silo Pharma Inc Info
Ticker SymbolSILO
Company nameSilo Pharma Inc
IPO dateJan 05, 2012
CEOWeisblum (Eric)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJan 05
Address677 N Washington Blvd
CitySARASOTA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code34236
Phone
Websitehttps://silopharma.com/
Ticker SymbolSILO
IPO dateJan 05, 2012
CEOWeisblum (Eric)
Company Executives of Silo Pharma Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Eric Weisblum
Mr. Eric Weisblum
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
211.93K
+7.07%
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
--
--
Mr. Daniel E. Ryweck
Mr. Daniel E. Ryweck
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Wayne D. Linsley
Mr. Wayne D. Linsley
Independent Director
Independent Director
--
--
Dr. Kevin Munoz
Dr. Kevin Munoz
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. Eric Weisblum
Mr. Eric Weisblum
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
211.93K
+7.07%
Dr. Jeff Pavell
Dr. Jeff Pavell
Independent Director
Independent Director
--
--
Mr. Daniel E. Ryweck
Mr. Daniel E. Ryweck
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Wayne D. Linsley
Mr. Wayne D. Linsley
Independent Director
Independent Director
--
--
Dr. Kevin Munoz
Dr. Kevin Munoz
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Anson Funds Management LP.
7.15%
SEG Opportunity Fund LLC
7.15%
Intracoastal Capital, L.L.C.
5.28%
AdvisorShares Investments, LLC
2.74%
Weisblum (Eric)
1.63%
Other
76.05%
Shareholders
Shareholders
Proportion
Anson Funds Management LP.
7.15%
SEG Opportunity Fund LLC
7.15%
Intracoastal Capital, L.L.C.
5.28%
AdvisorShares Investments, LLC
2.74%
Weisblum (Eric)
1.63%
Other
76.05%
Shareholder Types
Shareholders
Proportion
Corporation
12.43%
Hedge Fund
7.29%
Investment Advisor
2.93%
Individual Investor
1.67%
Research Firm
1.04%
Investment Advisor/Hedge Fund
0.39%
Other
74.26%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
25
587.46K
4.41%
+173.52K
2025Q2
29
967.79K
13.43%
+101.65K
2025Q1
29
441.37K
7.75%
-372.65K
2024Q4
27
376.44K
8.39%
-527.22K
2024Q3
26
523.23K
11.67%
-188.30K
2024Q2
22
344.51K
9.33%
-315.30K
2024Q1
18
291.15K
10.28%
-395.82K
2023Q4
18
333.21K
10.72%
-295.89K
2023Q3
17
578.11K
18.42%
-58.83K
2023Q2
16
572.24K
18.18%
-40.63K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SEG Opportunity Fund LLC
952.38K
7.15%
+952.38K
--
Sep 29, 2025
AdvisorShares Investments, LLC
184.24K
1.38%
+60.00K
+48.30%
Jun 30, 2025
Weisblum (Eric)
197.93K
1.49%
--
--
Aug 25, 2025
Geode Capital Management, L.L.C.
39.31K
0.3%
-5.18K
-11.64%
Jun 30, 2025
Two Sigma Investments, LP
43.22K
0.32%
+43.22K
--
Jun 30, 2025
The Vanguard Group, Inc.
16.33K
0.12%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
AdvisorShares Psychedelics ETF
1.78%
AdvisorShares Psychedelics ETF
Proportion1.78%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Silo Pharma Inc?
The top five shareholders of Silo Pharma Inc are:
SEG Opportunity Fund LLC holds 952.38K shares, accounting for 7.15% of the total shares.
AdvisorShares Investments, LLC holds 184.24K shares, accounting for 1.38% of the total shares.
Weisblum (Eric) holds 197.93K shares, accounting for 1.49% of the total shares.
Geode Capital Management, L.L.C. holds 39.31K shares, accounting for 0.30% of the total shares.
Two Sigma Investments, LP holds 43.22K shares, accounting for 0.32% of the total shares.
SEG Opportunity Fund LLC holds 952.38K shares, accounting for 7.15% of the total shares.
AdvisorShares Investments, LLC holds 184.24K shares, accounting for 1.38% of the total shares.
Weisblum (Eric) holds 197.93K shares, accounting for 1.49% of the total shares.
Geode Capital Management, L.L.C. holds 39.31K shares, accounting for 0.30% of the total shares.
Two Sigma Investments, LP holds 43.22K shares, accounting for 0.32% of the total shares.
What are the top three shareholder types of Silo Pharma Inc?
The top three shareholder types of Silo Pharma Inc are:
Anson Funds Management LP.
SEG Opportunity Fund LLC
Intracoastal Capital, L.L.C.
Anson Funds Management LP.
SEG Opportunity Fund LLC
Intracoastal Capital, L.L.C.
How many institutions hold shares of Silo Pharma Inc (SILO)?
As of 2025Q3, 25 institutions hold shares of Silo Pharma Inc, with a combined market value of approximately 587.46K, accounting for 4.41% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.02%.
What is the biggest source of revenue for Silo Pharma Inc?
In --, the -- business generated the highest revenue for Silo Pharma Inc, amounting to -- and accounting for --% of total revenue.
